Proteomics analyses were performed on the brains of wild-type (WT) controls and an Alzheimer's disease (AD) mouse model, APP/PS-1 human double mutant knock-in mice. Mice were given either drinking water or water supplemented with N-acetylcysteine (NAC) (2 mg/kg body weight) for a period of five months. The time periods of treatment correspond to ages prior to Ab deposition (i.e. 4-9 months), resembling human mild cognitive impairment (MCI), and after Ab deposition (i.e. 7-12 months), more closely resembling advancing stages of AD. Substantial differences exist between the proteomes of WT and APP/PS-1 mice at 9 or 12 months, indicating that Ab deposition and oxidative stress lead to downstream changes in protein expression. Altered proteins are involved in energy-related pathways, excitotoxicity, cell cycle signaling, synaptic abnormalities, and cellular defense and structure. Overall, the proteomic results support the notion that NAC may be beneficial for increasing cellular stress responses in WT mice and for influencing the levels of energy-and mitochondria-related proteins in APP/PS-1 mice.
Introduction
As the number of persons in the United States directly affected by Alzheimer' disease (AD) is expected to increase in the next 40 years to an estimated 16-20 million persons [1] , the need for preventative or modulatory therapies is pressing. While there are many types of compounds being explored as potential AD treatments, the oxidative stress hypothesis associated with AD has brought to the forefront the possible therapeutic utility of antioxidant compounds. This is based on the observed increase in reactive oxygen species (ROS) in AD brain that leads to downstream increases in protein oxidation [2] , DNA and RNA oxidation [3] [4] [5] [6] [7] , and lipid peroxidation [8] [9] . The oxidative stress present in AD brain is also a result of decreased endogenous antioxidant defenses [10] [11] and ultimately leads to neuronal death. Because of the profound consequences of oxidative stress in AD brain and reports that high doses of compounds such as a-tocopherol (vitamin E) may be effective in delaying disease progression [12] , the potential of antioxidant compounds as AD therapeutics seems promising.
Our laboratory has provided substantial evidence that amyloid-beta (Ab) , known to be heavily implicated in AD, mediates oxidative stress in AD brain [13] . Ab is derived from the amyloid precursor protein (APP) through cleavage of APP by b-and g-secretases, in which presenilin 1 (PS-1) is a component of the g-secretase complex. Genetic mutations in APP, PS-1, and PS-2 are associated with familial AD (FAD) [14] . PS-1 mutations lead to altered processing of APP and thus an increase in Ab peptides which are present as toxic oligomers or in senile plaques, pathological hallmarks of AD.
A mammalian model of FAD was developed by Borchelt et al. (licensed to Cephalon, Frazer, PA, USA), in which mice were backcrossed to carry the APP NLh /APP NLh Â PS-1 P264L /PS-1 264L mutations in order to humanize the mouse Ab sequence and to include the PS-1 mutation identified in human AD (APP/PS-1 human double mutant knock-in mice) [15] . APP/PS-1 mice have increased Ab production and accelerated amyloid deposition [15] . We have shown that neurons from APP/PS-1 mice (generated using the Cre-loc & knock-in technology) compared to wild type (WT) exhibit increased protein oxidation, lipid peroxidation, and susceptibility to oxidation by exogenous oxidants [16] . Furthermore, cerebral amyloid deposition increases in an age-dependent manner in APP/PS-1 mice [17] [18] [19] . Oxidative stress levels (as measured by protein carbonyls (PCO), 3-nitrotyrosine (3NT)-modified proteins, markers of protein oxidation, and 4-hydroxynonenal (HNE)-bound proteins, a marker of lipid peroxidation) also increase in brain in an age-dependent manner in APP/PS-1 knock-in mice when compared to WT controls [20] .
We recently explored the antioxidant, N-acetylcysteine (NAC), as an AD treatment at different disease stages in an APP/PS-1 human double mutant knock-in mouse model [21] . NAC is currently an FDA-approved drug for acetaminophen-based liver toxicity [22] and heavy metal poisoning. NAC serves as an antioxidant by indirectly increasing intracellular glutathione (GSH) levels and also acts directly as a free radical scavenger. Depletion of GSH is associated with many neurodegenerative disorders, including AD [11, 23, 24] ; however, dietary or pharmacological agents/mimetics that increase endogenous GSH levels can provide neuroprotection against oxidative stress [7, 13, 25] . That NAC increases endogenous GSH levels and protects brain from protein oxidation against hydroxyl radicals has been previously demonstrated in vivo [26] . NAC has also been shown to be partially protective in brain against peroxynitrite-induced damage [27] and protective against 3-nitropropionic acid [28] and acrolein-induced protein oxidation [29] . Furthermore, NAC restores memory and decreases oxidative stress in aged senescence-prone mice [30] .
As noted above, NAC provides protection against oxidative stress in the brains of APP/PS-1 human double mutant knock-in mice [21] . In those studies, drinking water was supplemented with NAC and administered daily to WT and APP/PS-1 mice for a period of five months beginning at ages of 4-and 7-months old. These ages correlate with the progression of amyloid deposition which begins at the age of 9 months, with elevated Ab (1-42) deposition in frank deposits occurring at 12 months [17] [18] [19] . By 9 months of age, Ab (1-42) deposition begins in APP/PS-1 mouse brain [19] and thus mimics pathological conditions of amnestic mild cognitive impairment (MCI), a transitional stage between normal aging, early dementia, and AD [31, 32] or early AD. Overall, in this previous study NAC provided neuroprotection against protein oxidation and nitration both prior to amyloid deposition (i.e. 9-month-old animals) and after amyloid deposition (i.e. 12-month-old animals) in APP/PS-1 human double mutant knock-in mice relative to WT [21] . In addition NAC treatment protected against lipid peroxidation when administered in the earlier age group [21] . Thus, NAC may potentially prevent some of the oxidative stress accompanying MCI and early stages of AD as well as reverse oxidative damage found during later stages of AD.
Herein, we seek to gain insights into the mechanisms reflective of Ab deposition and mechanisms governing the neuroprotection NAC provides against oxidative stress in the brains of APP/PS-1 human mutant double knock-in mice (hereafter referred to as APP/PS-1). To this end, proteomics analyses of the brains from 9-and 12-month-old WT and APP/PS-1 mice treated five months in vivo with or without NAC in the drinking water were performed. We hypothesized that (i) the brain proteome of APP/PS-1 mice at 9 months of age (beginning of Ab deposition) and 12 months of age (frank amyloid deposits) are different from WT mice, and (ii) in vivo NAC treatment causes changes in brain protein levels that are consistent with subsequent decreases in oxidative stress. 2-D PAGE coupled with MS analysis and database searching was used to detect differences in protein expression. The results are discussed with relevance to the effect Ab deposition has on the brain proteome and with relevance to potential in vivo NAC treatment in MCI and AD.
Materials and methods

Chemicals
Unless otherwise indicated, chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Animals and NAC administration
WT and APP/PS-1 human double mutant male mice were housed in the University of Kentucky Central Animal Facility. The APP/PS-1 mice were generated using the Creloc & knock-in technology by Cephalon and backcrossed to carry the APP NLh /APP NLh Â PS-1 P264L /PS-1 264L mutations in order to humanize the mouse Ab sequence and to include the PS-1 mutation identified in human AD [33, 34] . All animals were $30 g in size at the start of the experiments and were fed standard Purina rodent laboratory chow ad libitum on a 12 h light/dark cycle. Animals, both WT and APP/PS-1 mice, were provided with either drinking water or a 0.001% solution of NAC in drinking water (pH 7.2) for a period of 5 months. Treatments began with one group of animals at 4 months and a second group of animals at 7 months. These times were chosen based on previous studies [35] [36] , which correlate with Ab deposition. As noted, the mice employed begin to deposit Ab at 9 months of age. Thus, the 4-9-month period investigated brain prior to Ab deposition. These mice have frank amyloid deposition at 12 months of age. Thus, the 7-12-month period investigated NAC treatment during and after Ab deposition had begun and plaques had formed. New NAC solutions were provided every other day. Mice consumed $4 to 5 mL of water per day which amounts to a daily cumulative NAC dose of 2 mg/kg (body weight). Animals from both age groups were sacrificed after 5 months of treatment and brains were flash frozen with liquid nitrogen and stored at À801C until further use.
Preparation of brain homogenate
Brains were homogenized using 20 passes of a Wheaton tissue homogenizer into an ice-cold lysing buffer containing 4 mg/mL leupeptin, 4 mg/mL pepstatin, 5 mg/mL aprotinin, 2 mM EDTA, 2 mM EGTA, and 10 mM HEPES (pH 7.4).
Homogenates were centrifuged at 20 000 Â g for 10 min and the pellet was suspended in PBS. Pellet suspensions were washed twice with PBS by centrifugation at 32 000 Â g for 10 min. The supernatants were used in other studies of enzymatic activity [21] . The BCA method was used for protein concentration (Pierce, Rockford, IL, USA).
Brain homogenates (150 mg) were treated with 4 Â volume of 2N HCl at room temperature for 30 min. For protein precipitation, ice-cold 100% tricholoroacetic acid was added to a final concentration of 15% tricholoroacetic acid and allowed to react on ice for 10 min. Solutions were centrifuged at 14 000 Â g for 5 min at 41C, and precipitates were washed with 0.5 mL of 1:1 ethanol:ethyl acetate v/v four times by centrifugation at 14 000 Â g for 3 min at 41C. The protein pellets were then reconstituted in 200 mL of a rehydration buffer containing 8 M urea, 2 M thiourea, 50 mM DTT, 2% w/v CHAPS, 0.2% v/v Biolytes, and bromophenol blue. After one to two hours of mild vortexing, protein samples were ready for the first dimension of isoelectric focusing (IEF).
2-DE
Protein samples were loaded onto 11 cm, pH 3-10 Ready-IPG Strips (Bio-Rad, Hercules, CA, USA). After one hour, 2 mL of mineral oil was added to protein wells to reduce solvent evaporation. Proteins were taken up into strips by active rehydration at 50 V for 16-18 h. The conditions for IEF were as follows: 300 V for 1 h, a linear gradient to 8000 V for 5 h and finally, 20 000 V for 1 h. Focused strips were stored at À801C until the second dimension of gel electrophoresis was performed. For SDS-PAGE, thawed strips were equilibrated for 15 min in a buffer containing 50 mM TrisHCl (pH 6.8), 6 M urea, 1% w/v SDS, 30% v/v glycerol, and 0.5% DTT. Next, strips were reequilibrated in the same buffer containing 4.5% iodoacetamide rather than DTT. Strips were placed into Linear Gradient (8-16%) Precast Criterion Tris-HCl gels (Bio-Rad) and run at 200 V for $65 min.
SYPRO ruby staining
Following electrophoresis, gels were removed from the gel cassettes and placed in fixing solution (7% acetic acid v/v, 10% methanol v/v, in water) for 45 min on a rocker. Gels were submerged in SYPRO Ruby fluorescent gel stain (Bio-Rad) and allowed to shake overnight on a rocker. SYPRO Ruby was then removed and gels were stored in deionized water.
Image and statistical analysis
SYPRO Ruby-stained gels were scanned using a STORM phosphoimager (Molecular Dynamics, Sunnyvale, CA, USA) at excitation and emission wavelengths of 470 and 618 nm, respectively, and also saved in a TIFF format. PDQuest (Bio-Rad) imaging software was then used to match and align protein spots across the gels from the different treatment groups. In these experiments, a single 2-D gel was generated and analyzed for each biological replicate. Protein spots were normalized to the total density detected in each individual gel image. Proteins were considered to be statistically different between treatment groups based on a Z1.5-fold-change and a p-valueo0.05 (using a Student's t-test). It should be noted that herein we only assessed changes that occur between treatment groups at each time point independently (i.e. only 4-9 months or only 7-12 months). For example, in the 4-9-month-aged group, we made two way comparisons as follows: (i) WT given drinking water (WT H 2 O) versus WT given NAC-supplemented water (WT NAC), (ii) WT H 2 O versus APP/PS-1 H 2 O, and (iii) APP/PS-1 H 2 O versus APP/PS-1 NAC. A Student's t-test was used to determine statistical differences between treatment groups.
In-gel trypsin digestion
Protein spots of interest were excised from SYPRO Rubystained gels with a clean blade and transferred into a 0.5 mL Eppendorf microcentrifuge tube. Excised gel pieces were washed with 0.1 M NH 4 HCO 3 buffer at room temperature for 15 min. ACN was added and allowed to incubate for 15 min. The mixed solution was removed and the gel pieces were allowed to dry in the tubes under a flow hood for 30 min. Next, gel pieces were incubated with 20 mM DTT in 0.1 M NH 4 HCO 3 at 561C for 45 min. The DTT solution was removed and gel pieces were incubated with 55 mM iodoacetamide in 0.1 M NH 4 HCO 3 for 15 min. The solution was removed and gel pieces were incubated with 50 mM NH 4 HCO 3 for 15 min, followed by the addition of ACN for 15 min. This mixed solution was removed and gel pieces were allowed to dry for 30 min in a flow hood. A solution of 20 ng/mL modified trypsin (Promega, Madison, WI, USA) in 50 mM NH 4 HCO 3 was added to gel pieces in order to submerge them and were allowed to shake overnight at 371C.
MS and database searching
Tryptic solutions were removed from gel pieces and transferred to a new microcentrifuge tube. Additional tryptic peptides were extracted from gel pieces by addition of 5 mM NH 4 HCO 3 for 10 min with sonication. Next, 95% acetonitrile in 1 mM NH 4 HCO 3 was added for another 10 min with sonication. This supernatant was combined with the previous tryptic solution and concentrated to a small volume ($10 mL). C18 ZipTips (Millipore, Billerica, MA, USA) were used to remove salts from samples prior to MS analysis. Samples were loaded into a 96-well plate rack for nanoelectrospray infusion using an Advion Tri-Versa Nanomate (Ithaca, NY, USA). Electrosprayed peptides were analyzed with an LTQ-Orbitrap XL (ThermoScientific, Waltham, MA, USA) mass spectrometer. The Orbitrap was set to acquire a full MS scan at 60 000 resolution and in data-dependent mode the eight most intense ions were selected for fragmentation and mass analyzed in the Orbitrap at 30 000 resolution. 
Western blotting
Samples (100 mg) from the 7-12-month treatment group were incubated with sample loading buffer for protein denaturation and subject to electrophoresis on a 12.5% SDSpolyacrylamide gel. Proteins were transferred to a nitrocellulose membrane at 90 mA/gel over a 2 h period. Nitrocellulose membranes containing the transferred proteins were blocked for 1 h in fresh wash buffer (PBS, 150 mM NaCl, 0.05% Tween 20, pH 7.4) containing 3% BSA, and incubated with a 1:2000 dilution of anti-mouse enolase monoclonal antibody (Santa Cruz Biotechnologies; Santa Cruz, CA, USA) and anti-mouse actin antibody (SigmaAldrich) in wash buffer for 2 h. The membrane was washed Figures 1 and 2A-C show examples of typical 2-D gel images of proteins isolated from the brains of WT and APP/ PS-1 mice given drinking water or NAC-supplemented drinking water from 4-9 or 7-12 months of age. Protein spots that were differentially expressed between the various treatment groups (as described above) and identified with MS are labeled in the figure and listed in Tables 1 and 3 . As shown in Tables 1 and 3 , the probability for false protein identifications with SEQUEST was o1eÀ03 for all proteins indicating high confidence in spot assignments. Proteins were identified with at least two different peptide sequences and multiple peptide hits corresponding to every MS/MS event resulting in significant peptide identification. For example, aconitate hydratase (ACO2) was identified with six peptide sequences from 23 multiple MS/MS spectra ( Table 1) .
Effect of NAC on brain protein levels in WT mice
Following in vivo NAC treatment in 9-month-old WT mice, the proteins, fructose bisphosphate aldolase A (142.6m, p-valueo0.04) and superoxide dismutase 2 (SOD2) (6.75m, p-valueo0.04) were significantly increased in expression (Table 2) . Prohibitin (2.95m, p-valueo0.01) was significantly increased, while cofilin 1 (0.56k, p-valueo0.04) was significantly decreased in 12-month-old WT mice (Table 4) .
Comparison of WT versus APP/PS-1 mice
Several brain proteins were differentially expressed in comparisons of WT and APP/PS-1 mice given drinking water at 9 months (Table 2) . Synaptosomal-associated 
Effects of NAC treatment of APP/PS-1 mice
Glutamate dehydrogenase 1 (GDH), mitochondrial (1.88m, p-valueo0.03), was significantly increased in 9-month-old APP/PS-1 NAC mice relative to APP/PS-1 H 2 O. The proteins a-enolase (60.6m, p-valueo0.05) and pyruvate kinase isozymes M1/M2 (4.60m, p-valueo0.005), had significantly increased levels of 12-month-old APP/PS-1 NAC mice (Table 4) . Recent studies in our laboratory investigated the expression levels of Pin1 using Western blot analysis and determined that Pin1 was significantly decreased in the brains of APP/PS-1 mice relative to WT controls [21] at 12 months of age and Pin1 levels slightly increased after in vivo NAC treatment. These results are consistent with these observations that Pin1 is significantly decreased in the brains of 12-month-old APP/PS-1 H 2 O mice relative to WT H 2 O mice (see Table 4 ).
Western blotting analysis
Western blotting analysis was performed to validate changes in protein expression for a-enolase in the 7-12-month treatment group. Figure 3A shows a Western image of three samples from each treatment group after being probed with primary enolase antibody (actin was used as a loading control). Figure 3B is a histogram plot representation of the results in which no significant changes are detected in normalized enolase expression levels across the treatment groups. However, there is a trend towards increased enolase expression in APP/PS-1 mice given drinking water treated with NAC relative to APP/PS-1 mice given drinking water. This result is generally consistent with the proteomics results reported above in Table 4 . We note that the additional band most likely comes from a non-specifically bound protein. A total n 5 3 used to measure the Western blots for enolase is small relative to the entire population of animals used in each group (i.e. n 5 8 or n 5 9) and could contribute to differences in the ratio differences measured by the two techniques. As noted above, one or two animals may have outlier ratios. We randomly chose a smaller subset of each group to carry out the validation study. Additionally, differences in the measured percent change in Western blots and the 2-D gel blots could also be due to dynamic range limitations in colorometric staining as opposed to greater sensitivity with Sypro Ruby fluorescent staining, respectively. Finally, some of the largest changes measured in 2-D gel analyses may be overestimated based on the software algorithm that estimates a threshold density value for missing or low-level spots.
Discussion
Substantial evidence exists that Ab (1-42) significantly contributes to oxidative stress in AD and in in vitro and in vivo model systems of AD [2, 13, 37] . As a part of this ongoing work, we have investigated the levels of oxidative stress in APP/PS-1 mice [20] at ages that correlate with the start of Ab deposition and plaque formation in the brain [35] . The levels of PCO, 3-NT-modified proteins, and HNEbound proteins are increased in APP/PS-1 mice relative to WT controls [21] . Simultaneously, the increase in oxidative stress levels correlate with an increase in soluble Ab, Ab load, and non-neuritic and neuritic plaques [38] . We note that while Ab deposits are generally localized to the hippocampus and cortex regions, we examined entire brain homogenates as beneficial effects of NAC may appear in regions other than where plaques are localized. Key to the work reported herein is the ages that were used for investigation (i.e. 4-9 month-and 7-12 month-old mice) of the effects of Ab deposition and effects of in vivo NAC treatment on the brain proteome of APP/PS-1 mice. These ages correspond to animals that have similar pathology to that observed in MCI and AD patients, respectively, and correlate with periods of NAC treatment given prior to and after amyloid deposition and plaque formation. a) The protein accession number found in the Swiss-Prot (mouse) database.
b) The number of peptide sequences identified by ESI-MS/MS. The total number of peptide hits is indicated in ( ), including multiple hits across different charge states. c) The probability associated with a false protein identification using the SEQUEST search algorithm.
Based on the proteomics results obtained, we observe several proteins whose brain levels are altered in APP/PS-1 mice relative to WT controls in both the 4-9-month and 7-12-month groups given drinking water. Below we discuss biological processes of proteins that are substantially altered in APP/PS-1 mice and where applicable, the potential benefits of NAC in influencing protein levels in WT and APP/PS-1 mice. Some of the changes reported in Tables 2  and 4 are consistent with results obtained from studies in our laboratory that have previously investigated changes to the proteomes of oxidized proteins in AD and MCI [39] [40] [41] [42] [43] .
Energy-related enzymes
Alterations to proteins involved in various aspects of energy production through changes in expression levels or modifications could contribute to the overall dysregulation in glucose metabolism evidenced in AD [39] [40] [41] [42] [43] [44] . Prior to Ab (1-42) deposition (e.g. 4-9 months) the subunits of ATP synthase protein, a and d, have decreased expression in APP/PS-1 H 2 O mice relative to WT H 2 O mice. On the other hand, the V-type proton ATPase subunit B, which is the brain specific isoform, is increased in Fig. 1 for the location of these spots. a) The protein accession number found in the Swiss-Prot (mouse) database.
b) The number of peptide sequences identified by ESI-MS/MS. The total number of peptide hits is indicated in ( ), including multiple hits across different charge states. c) The probability associated with a false protein identification using the SEQUEST search algorithm. APP/PS-1 H 2 O mice relative to WT H 2 O mice. In the 7-12-month-old group, ATP synthase subunit a was observed to be increased in APP/PS-1 H 2 O mice relative to WT H 2 O mice. ATP synthase is involved in the synthesis of ATP and work by utilizing a proton gradient that is established through the electron transport chain (ETC) located in the inner mitochondrial membrane coupled to complex physical rotations of components of this complex [45] .
Cox5A levels were increased in the brains of APP/PS-1 H 2 O mice relative to WT H 2 O in the 4-9-month treatment group and decreased in the 7-12-month treatment group. Cox5A is a mitochondrial enzyme involved in the final aspects of the ETC by providing reducing equivalents from cytochrome C to oxygen [46] . Elevated expression of Cox5A prior to substantial Ab deposition could increase the amount of ROS present by leading to increased numbers of electrons coming out of the ETC. Alternatively, increased Cox5A expression could lead to better mitochondrial function to provide ATP. Decreased Cox5A expression however, may be an indirect or direct result of increased levels of Ab deposition and correlate with increased levels of ROS and oxidative stress. It is possible that while we measure decreased Cox5A expression in the 7-12-month animals, there may be a concurrent increase in Cox5A oxidation due to increased oxidative stress. Additional experiments, such as redox proteomics, would be necessary however to support this hypothesis.
a-Enolase, fructose-bisphosphate aldolase C, GAPDH, and pyruvate kinase are enzymes important in the glycolytic and tricarboxylic acid (TCA) cycles and ATP production. Previous studies that investigated expression changes in the hippocampal region of brains from AD subjects observed significant increases in the levels of these proteins relative to age-matched controls [41] . Herein, we observed differing trends that may be a result of species differences and/or the lack of neuronal death and neurofibrillary tangles in APP/ PS-1 mice. Decreased expression levels of a-enolase, fructose-bisphosphate aldolase C, and GAPDH in the brains of 4-9 month-old APP/PS-1 H 2 O mice may be directly reflective of lower glucose metabolism and ATP available in the brain. These mice have levels of Ab deposition and plaque formation that are lower than that observed in 12-month-old animals whom better mimic the pathology observed in later stages of AD. Additionally, in the 7-12-month treatment group, NAC significantly increases a enolase and PK expression, suggesting that NAC through downstream mechanisms may influence certain aspects of glucose metabolism, entry into the TCA cycle, and glutamate synthesis.
Excitotoxicity
GS was reported as oxidatively modified in AD brain, [47] [49] and AD [50] . These data are consistent with the reports of altered Ca 21 levels in APP and other model systems of AD [51] [52] [53] .
Cell cycle, tau phosphorylation, and Ab production
Increased oxidation, decreased levels, and decreased activity of Pin1 in AD and MCI brain has been reported [54, 55] . Similarly, decreased levels and activity of Pin1 exist in the brains of APP/PS-1 H 2 O mice relative to WT H 2 O mice in 9-and 12-month-old mice [21] . Pin1, by binding to p-Ser/p-Thr-Pro motifs and conversion of the Pro residue of the target protein from cis-to-trans conformation and vice versa, regulates the activity of target proteins [56] . In particular, Pin1 regulates target Tau-relevant kinases and protein phosphatase 2A, important for the phosphorylation/dephosphorylation of tau, and is necessary for cell growth and proper cell cycle functions [57, 58] . Pin1 has also been implicated in Ab production, in which Pin1 inhibition promotes APP processing in the amyloidogenic pathway and therefore causes elevated levels of Ab [48, 59] and oxidative stress [13, 60] . This result is consistent with and may contribute to elevated numbers of senile plaques in AD and in neuritic plaques in this APP/ PS-1 model [38] .
Synaptic abnormalities
One pathological hallmark of AD is synapse loss [61] . SNAP-25 is a synaptosomal protein that is a part of the Q-SNARE complex that functions in neurotransmitter release at neuronal synapses. SNAP-25 is also involved in vesicular docking and associates with proteins such as syntaxin to anchor vesicles to their target membranes. This protein is oxidatively modified in AD brain [60] and has increased levels in brains from APP/PS-1 H 2 O mice relative to WT H 2 O mice. SNAP-25 elevation in APP/PS-1 mice brain conceivably may be a response to oxidative stress or decreased synaptic counts or an attempt to improve neurotransmission in this mouse model of AD.
Defense systems
Heat shock protein 90a is a molecular chaperone protein that is induced in conditions of stress response. This elevated expression serves to protect cells from damaging effects caused by stress through maintaining proper folding/unfolding of proteins. HSP90a is significantly decreased in 9-month-old APP/PS-1 H 2 O mice suggesting a lack of sufficient brain defenses in place to combat oxidative stress.
Structural proteins
Dynamin 1 was significantly decreased in APP/PS-1 H 2 O mice in the 7-12-month group. Among its functions, dynamin is an inhibitor of phosphatidylinisotol 3-kinase and has been reported to be elevated in brains of aged mice, an elevation that leads to cell death [62] . However, in AD, dynamin mRNA and protein levels are significantly decreased and may be associated with altered synaptic vesicle recycling and endocytosis [63] . Additionally, dynamin was also observed to be decreased in the olfactory bulbs of old mice relative to young mice which may be a regional specific expression [64] . Lower levels of dynamin in 12-month-old APP/PS-1 H 2 O mice conceivably could be related to lessened synaptic vesicle recycling due to lower numbers of synapses.
Mitochondrial proteins
With aging, the activity of ACO2, mitochondrial matrix enzyme, is altered [65, 66] , and has decreased expression in aged rats [67] . ACO2 in brain is oxidatively modified in AD by the lipid peroxidation product, HNE [68] . ACO2 was significantly decreased in the 4-9-month treatment group in APP/PS-1 H 2 O mice.
Effects of NAC on the proteome of WT mice
Fructose bisphosphate aldolase A and SOD2 were significantly increased in 9 month-old WT mice treated with NAC relative to WT H 2 O. Fructose bisphosphate aldolase A is an enzyme involved in the glycolytic pathway. SOD2, also known as MnSOD, is an antioxidant enzyme localized in the mitochondrion that protects cells from toxic superoxide anion. Elevated SOD2 upon in vivo NAC treatment in WT mice may be an early protective mechanism against augmented oxidative stress which is known to increase with aging.
In the 12-month-old age group, NAC treatment of WT mice led to prohibitin being significantly increased and cofilin 1 significantly decreased in brain. Prohibitin is localized to the inner mitochondrial membrane and is known to inhibit DNA synthesis, regulate the cell cycle, and be involved in apopotosis and aging [69] . Prohibitin has shown cellular defense against oxidative stress in epithelial cells [70, 71] and decreases in expression as a function of cellular senescence in human and chicken fibroblasts [69] . Because prohibitin also has roles as a chaperone and participates in the assembly of subunits in the mitochondrial respiratory chain complex, this protein regulates mitochondrial respiratory activity and aging [72, 73] . Elevated prohibitin expression following NAC may be helpful in delaying detrimental changes associated with mitochondrial respiration in aging by increasing the availability of components involved in the ETC. Cofilin 1 is the non-muscle isoform of cofilins that constitute a major portion of actin rods and plays roles in actin depolymerization and polymerization. Taken together, the results suggest that NAC, which many persons use as an over-the-counter dietary supplement, can affect levels of brain proteins involved in metabolism, prevention of oxidative stress, mitochondrial function, and cytoskeletal integrity. Each of these processes could be important in slowing mitochondrial alterations associated with aging.
Examining the proteomes of WT and APP/PS-1 mice given drinking water prior to (i.e. 9 months) and after (i.e. 12 months) periods of significant Ab (1-42) deposition revealed several altered brain proteins involved in energy production, cell signaling, defense systems, excitotoxicity, synapse-related, cellular structure, and mitochondria in APP/PS-1 mice. In vivo NAC treatment for 5 months has been reported to provide protection against oxidative stress in brain of APP/ PS-1 human double mutant knock-in mice at 9 and 12 months of age, consistent with the notion that NAC has potential to be a therapeutic approach for both MCI and AD [21] . NAC provides protection against oxidative stress because it acts as a free radical scavenger directly and increases endogenous GSH levels. Our results show that NAC alters the expression levels of some proteins in the brain proteomes of WT and APP/PS-1 mice. It is possible larger numbers of proteins affected by NAC may be detectable in specific cell types or tissues (e.g. hippocampus and/or cortex) and global effects in brain are minimized in these studies. Studies of this nature and others that investigate the possibility for NAC as a potential therapeutic approach in MCI and AD are strongly suggested and are currently ongoing in our laboratory.
